Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Sees Significant Drop in Short Interest

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totaling 3,004 shares, a decline of 78.4% from the September 30th total of 13,919 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 19,959 shares, the days-to-cover ratio is currently 0.2 days.

Emmaus Life Sciences Price Performance

Shares of OTCMKTS:EMMA remained flat at $0.04 during trading on Thursday. 7,202 shares of the stock were exchanged, compared to its average volume of 104,302. Emmaus Life Sciences has a twelve month low of $0.01 and a twelve month high of $0.09. The firm has a market cap of $2.86 million, a P/E ratio of -0.45 and a beta of 10.07. The stock has a 50 day moving average of $0.06 and a 200-day moving average of $0.02.

Emmaus Life Sciences (OTCMKTS:EMMA) last posted its quarterly earnings data on Friday, August 14th. The company reported $0.02 EPS for the quarter. The firm had revenue of $6.32 million for the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and debilitating diseases. The company’s best-known product is Endari, an oral powder formulation of L-glutamine approved in the United States to reduce the frequency of acute complications associated with sickle cell disease in adults and children aged five and older.

Emmaus has focused its research and development activities on therapies for diseases with significant unmet medical needs, including hematological and other rare disorders.